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Abstract 
Objective: Predictors of morbidity and mortality after Status Epilepticus (SE) have 
been extensively studied in hospital- and population based cohorts. However, little 
attention has been directed towards SE recurrence after an incident episode. We 
investigated clinical and demographic characteristics of patients presenting SE 
recurrence, and its specific prognostic role.  
Methods: In this observational cohort study, we screened our prospective registry of 
consecutive adults with SE between April 2006 and February 2014. Demographic and 
clinical data were compared between incident and recurrent SE episodes; risk of SE 
recurrence was assessed through survival analysis, and the prognostic role of SE 
recurrence with multivariable logistic regressions.  
Results: Of the incident cohort (509 patients), 68 (13%) experienced recurrent SE. 
The cumulative recurrence rate over 4 years was 32 %. Recurrence risk was 
significantly reduced after an acute SE etiology (HR: 0.5; 95% CI: 0.31-0.82, 
p=0.005), and was borderline increased in women (HR: 1.59; 95% CI 0.97-2.65, 
p=0.06). While recurrent SE episodes showed lower morbidity and mortality, 
prognosis was independently related to SE severity (STESS score) and potentially 
fatal etiology, but not to SE recurrence. 
Significance: This study provides class III evidence that SE recurrence involves a 
significant proportion of patients, and that recurrence risk is independently associated 
with chronic etiology and to a lesser extent with female gender. However, contrary to 
underlying cause and SE severity, SE recurrence per se does not independently 
correlate with outcome. Early identification of patients at higher risk of SE recurrence 
may influence their management during follow-up. 
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Status epilepticus (SE) represents a neurological condition with considerable risk of 
morbidity and mortality1-3; etiology, increasing age, severe impairment of 
consciousness prior to treatment, and de novo presentation, have been independently 
associated with an unfavorable outcome4-7. It has also been shown that a consistent 
proportion of patients surviving a refractory SE episode will subsequently develop 
epilepsy8, 9, suggesting that SE can be considered, at least in some situations, as the 
hallmark of a major epileptogenic insult. However, relatively little is known about SE 
recurrence in survivors after an incident SE; to the best of our knowledge, only one 
population-based study specifically addressed the risk of recurrence after a first 
afebrile SE episode10.  The population-based studies conducted in Richmond in 1996 
and in Germany in 2001 mentioned SE recurrence rate2, 11 without further analyses. 
Furthermore while pre-existing epilepsy has been reported to be a factor of relatively 
good prognosis in patients with incident SE6, 11, it is still not clear if SE recurrence 
also independently portends a better prognosis as compared to incident episodes. 
Moreover, identifying subjects at high risk of recurrent SE would be potentially useful 
in order to adapt their clinical follow-up. 
To address these issues, we investigated clinical and demographic characteristics of 
patients presenting recurrent SE, factors related to SE recurrence and their specific 
prognostic role.  
 
Methods 
Patients and SE definition 
We analyzed our prospective registry of consecutive adult patients with SE12 treated 
in our center between April 1st 2006 and February 28 2014 (94 months). SE was 
defined as continuous seizures for longer than 30 (until 2008), or five minutes (since 
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2008, in line with the operational definition13, 14). Patients younger than 16 years old 
(pediatric age with potentially different epidemiological implications), or with post-
anoxic coma (in view of the almost invariable dismal outcome), were not included in 
this registry. After reviewing the computerized medical records of our hospital, 
subjects with incident SE prior to the study period (treated either inside or outside our 
institution) or with incomplete clinical data were excluded. The population covered 
by our hospital represents about 250’000 habitants as first-line, and up to 1’000’000 
as a third-line center. In the context of the SE registry, this observational cohort study 
was fully approved by our Ethic Commission.  
 
Definition of Variables  
During each admission, demographic and clinical data were prospectively collected 
using the best available source, as previously outlined12. The STESS (Status 
Epilepticus Severity Score), a validated clinical score15, 16, was calculated before 
treatment initiation (0-2: favorable, 3-6: unfavorable outcome). Etiology was 
classified according to criteria of the International League Against Epilepsy13; as 
previously reported by us and others17, 18, we further classified etiologies as 
“potentially fatal” if potentially leading to death independently of SE (e. g., acute 
large vessel ischemic stroke, acute cerebral hemorrhage, acute central nervous system 
infection, severe systemic infection, malignant brain tumor, acquired 
immunodeficiency syndrome with central nervous system complications, chronic 
renal failure requiring dialysis, systemic vasculitis, metabolic disturbance or acute 
intoxication sufficient to cause coma in the absence of SE). Conversely, antiepileptic 
drug (AED) withdrawal, an acute etiology, and remote or progressive symptomatic 
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causes such as brain trauma, stroke, slow evolving dementia, multiple sclerosis or 
meningioma, were not considered as potentially fatal.  
 
The worst seizure type for each incident SE episode was classified in increasing order 
of severity as absence, generalized myoclonic (in genetic generalized epilepsy), 
simple partial (focal without consciousness impairment), complex partial (focal with 
consciousness impairment), generalized convulsive (GC), and non-convulsive 
associated with coma (NCSEC); EEG was required to diagnose non-convulsive 
episodes. Refractory SE was defined in episodes after failure of the first and second 
treatment lines12. At hospital discharge, outcome was prospectively categorized into 
return to baseline clinical conditions, survival with neurologic sequelae, or death. 
Status Epilepticus recurrence during the study period was assessed through screening 
of our prospective SE registry.  
 
Statistical analysis  
Comparisons of clinical variables between incident and recurrent SE episodes were 
performed using two-sided Fischer, t, and χ2 tests, as needed. The SE recurrence rate 
was estimated using a survival analysis (considering the number of patients and not of 
SE episodes), where patients lost to follow-up were censored at their last visit at our 
hospital (regardless of the department; assessed though the computerized chart 
review), and deceased subjects at their date of death; the effect of different clinical 
factors was examined through univariable and multivariable Cox regression analyses. 
Outcome predictors (mortality, return to baseline clinical conditions) were 
investigated with stepwise multivariable logistic regressions; goodness of fit of the 
models was assessed with the Hosmer-Lemeshow test. Calculations were performed 
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with the Stata Software, version 12 (College station, TX) and SPSS version 20 (SPSS 
Inc. Chicago, Illinois); significance was set as p<0.05.   
 
 
Results 
Cohort characteristics 
Of the 650 SE episodes prospectively recorded in the database during the study 
period, 41 had to be excluded: 34 (5%) were found to have presented an incident SE 
prior to the study period, and 7 (1%) had incomplete data available. Among the 
remaining 609 SE episodes, 509 (84%) incident and 100 recurrent SE episodes were 
studied; 562 (93%) episodes (470 incident and 92 recurrent) lasted more than 30 
minutes.   
 
Table 1 illustrates demographic and clinical variables of the studied cohort. While 
441 patients had only incident events (203 women, 238 men), 68 patients of the 
incident group of 509 patients (13%) experienced SE relapses during the 8-years 
study period; 53 had only one recurrence (26 women, 27 men), while 15 had two or 
more relapses (13 women, 2 men: 8 with 2 relapses, 3 with 3 relapses, 3 with 5 
relapses, and 1 with 7 relapses). Among the 470 incident SE that lasted more than 30 
minutes, there were 61 that recurred (13%), whereas 18% (7 / 39) of incident SE that 
lasted between 5 and 29 minutes experienced relapses. Within recurrent SE episodes, 
there was a higher prevalence of women with a lower STESS (median score of 2, 
suggesting a favorable outcome), and a smaller proportion of subjects with 
GCSE/NCSEC and potentially fatal etiologies.  
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Risk and predictors of SE recurrence 
To investigate the variables associated with a SE recurrence risk, we conducted a 
survival analysis (Figure 1A): the overall cumulative SE recurrence rate was 32% at 
4 years, with a median follow-up of 0.32 years (range: 1 day - 8.2 years). Table 2 
illustrates demographical and clinical variables related to the risk of SE recurrence in 
the survival analysis: an acute symptomatic etiology (HR 0.5, 95%CI 0.31-0.82, 
p=0.005), and, to a lesser extent, female gender (borderline significant, HR: 1.6, 95% 
CI: 0.97-2.65, p=0.06) were independently related to SE recurrence. To highlight the 
role of etiology, Figure 1B shows the cumulative survival rate without recurrence, 
depending on the acuteness of the underlying cause. Among recurrent SE episodes, 
the three leading causes were AED withdrawal (33%), previous stroke (18%), and 
brain tumor (14%); the distribution of etiologies among genders was not significantly 
different, in analogy with the prevalence of acute or potentially fatal causes.   
 
Outcome 
Mortality rates in incident and recurrent SE episodes are shown in Figure 2. Seventy-
four patients (12% of all patients; 15% of those with only incident SE: 39 men and 35 
women) and 6 (2% of all patients; 11% of subjects with one recurrent SE: 5 women, 1 
man) died, while no fatality was noted in the group with 2 or more recurrences. 
Following incident SE, a return to baseline clinical condition was recorded in 254 
(50%) patients, as compared to 63 (63%) of subjects experiencing recurrent SE 
episodes (p=0.017, X2). A stepwise multivariable logistic regression, considering 
variables associated with lack of return to baseline, identified potentially fatal 
etiology (OR: 3.05; 95% CI: 2.14-4.34) and a higher STESS (OR: 1.63; 95% CI: 
1.43-1.87), but not SE recurrence (OR: 0.9; 95% CI: 0.55-1.47); the model had an 
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acceptable goodness of fit (P=0.123, Hosmer-Lemeshow). Analysis of mortality, 
considering only the last SE episodes for each patient, identified the same variables: 
potential fatal etiology (OR: 3.03; 95% CI: 1.74-5.30) and increasing STESS (OR: 
1.60; 95% CI: 1.31-1.93), with an acceptable goodness of fit (p=0.551, Hosmer-
Lemeshow), while incident as compared to recurrent SE episodes was, again, not 
significant.   
 
Discussion 
This study, based on a hospital-based cohort and using a conservative assessment of 
follow-up, provides Class III evidence 19 that SE recurrences involve 32% of patients 
at 4 years, and that the lack of an acute symptomatic etiology for the incident SE 
episode, and to a lesser extent a female gender, independently correlate with a higher 
risk of SE recurrence. While survival was higher among patients with recurrent SE 
episodes, mortality and morbidity following SE are related to the underlying clinical 
profile of the patient, but not SE recurrence itself.  
 
The crude recurrence rate over 8 years was 13% (68 of 509 patients); nevertheless, in 
order to account for patients lost to follow up or dying during the study period, a 
survival analysis was performed, which identified a recurrence rate of 32 %. This is 
strikingly similar to the population-based study specifically designed for this question, 
based on a Rochester (MN) cohort, which retrospectively found a recurrence of 32% 
over 10 years (with 82% of recurrences presenting within 2 years)10. It appears 
however clearly higher than 10% over 7 years reported in a retrospective hospital-
based cohort in Boston (MA)6, and than 13% over two years in the Richmond and 
German population-based studies2, 11. These important differences probably relate to 
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different methodologies, such as prospective versus retrospective assessments, 
hospital versus population-based cohorts, and possible under-ascertainment in some 
retrospective studies.  
 
Women with focal SE, a lower STESS score, and without potentially fatal etiologies 
were significantly more frequently found among patients experiencing recurrent SE. 
The survival analysis allows assessing if these variables represent predictors of 
recurrence, or are rather biased by mortality in incident SE episodes or loss to follow-
up; this approach showed that an etiology other than acute symptomatic at incident SE 
independently forecasts SE recurrence: as much as 50% of patients without an acute 
etiology will indeed recur within 4 years. This observation is reminiscent of the 
situation following incident seizures8, but differs somewhat from the findings of the 
afore-mentioned US study on SE relapse, which showed that the risk of recurrence 
was influenced by progressive symptomatic, but not acute symptomatic conditions10. 
While in that study response to the first antiepileptic agent was inversely correlated 
with the risk of recurrence10, in our analysis SE refractoriness (i.e., response to the 
first two treatments) was not. These discrepancies may reflect, at least in part, the 
markedly different period between the two studies (1965-1984 versus 2006-2014), 
which probably influenced not only diagnosis, but also treatment protocols. Of note, 
in our registry the vast majority of patients received a second agent; this represents a 
common practice in an emergency clinical setting20.  
 
The tendency to a female predominance in subjects with recurrent SE (borderline 
significant in our survival analysis) has been previously outlined10, and might reflect 
the fact that men tend to be more prevalent than women among incident SE patients11, 
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20, with a trend towards a higher mortality4, 21, even if several studies do not consider 
gender as an independent risk factor for death5-7. This aspect might be at least in part 
explained by different comorbidities depending on the gender; for example, males 
suffer more frequently from cardiovascular diseases than women4, 22, and SE 
associated with stroke portends a higher mortality at the incident episode23. However, 
while in our analysis we did not consider medical comorbidities (these were shown to 
have only a limited impact on SE prognosis24), there was no significant difference in 
terms of specific etiologies among men and women experiencing a SE relapse. 
 
Mortality and morbidity, significantly less frequent in recurrent SE, were related to 
the severity of each SE episode, rather than the recurrence itself. An underlying 
severe SE etiology was the most important predictor of poor outcome in our cohort, in 
line with several prior studies on SE prognosis4-7, 24, 25; however, those studies did not 
specifically take into account recurrence status. Furthermore, the STESS, reflecting 
episode severity, also represents an independent marker of poor prognosis, as already 
found in former studies in our12, 24 and other cohorts15, 16. In the present analysis, 
GCSE and NCSEC were associated with incident SE without recurrence, a finding 
that has been previously mentioned6. An explanation could be that these seizures 
types may represent more severe SE episodes, with lower likelihood of survival6, 15, or 
that consequent anticonvulsant treatment initiated at the first episode prevents 
relapsing episodes. It has already been showed that the degree of neuronal damage 
after a SE depends on its duration; it is therefore possible to postulate that a longer SE 
causes greater neuronal injury that can act as a chronic trigger for recurrent SE 26 .  
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To best of our knowledge, this represent the first hospital-based study comparing 
incident and recurrent SE in adults, analyzing survival free of SE recurrence and its 
relationship with clinical variables; furthermore, we assessed a contemporary cohort 
of patients over a clearly defined time span. The previous retrospective population-
based study10 included a pediatric population, with peculiar clinical aspects that are 
often different from adult SE (e.g., different rates of infections, genetic abnormalities, 
and cerebral malformations), the studied population was considerably smaller, and the 
time span (extending between 1965 and 1984) may have significantly influenced SE 
diagnosis and management, as stated previously. Furthermore, the population-based 
study conducted in Germany in 2001 and in Richmond in 1996 also mentioned SE 
recurrence rate, but did not attempt identifying risk factors for recurrence, nor its 
specific prognostic role2, 11.  
 
Our study has some limitations. First, it is limited to a single-center, hospital-based 
cohort; therefore, some SE episodes may have been treated in other hospitals. 
However, it seems unlikely that a significant proportion of recurrences were missed, 
as we showed that SE episodes treated exclusively in regional hospitals of our region 
represented only 11% of the SE episodes treated in our center27. Furthermore, the 
present design allowed a uniform, prospective collection of comprehensive clinical 
data, likely conferring a strengthened internal validity. Second, despite an 8-year 
period study, the median follow up was only 0.3 years (up to 4 years) for each patient; 
this was, however, calculated rather conservatively. If we had assumed that lack of 
further clinical notes in our computerized database implied recurrence-free survival, 
we would have underestimated the recurrence following overestimation of the 
denominator: it seems indeed likely that several patients do not die in the third-level 
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hospital, but rather at home or in peripheral facilities. We acknowledge that further 
efforts to trace survivors lost to follow-up were not undertaken, since this study was 
approved by the Ethics Committee as a purely observational, without any contact to 
patients. Third, there is a lack of information about chronic antiepileptic treatment 
during follow up, apart from drug withdrawal as a SE etiology. While it was recently 
outlined that adherence to treatment guidelines is not related to SE prognosis28, we 
acknowledge that it is impossible to formally exclude that this aspect might have 
somewhat influenced the recurrence rate. Fourth, additional recurrent seizures lasting 
less than five minutes during following up were not taken into account in the analysis. 
Therefore, it was not possible to assess if SE recurrences were part of epilepsy 
following an incident SE episode, but this study aimed to analyze specifically SE, the 
most severe expression of epileptic seizures. Etiology categorization as potentially 
fatal is somewhat arbitrary, but has been showed to better account to the outcome than 
the ILAE etiological definition.17,18 
 
Conversely, we undertook great caution in excluding patients having presented an 
incident SE episode before the study period (5% of the whole cohort, broadly 
comparable to the non adjusted overall 13% recurrence rate of SE), while some 
previous studies6, 11 did not mention this information in their exclusion criteria. We 
included patients with SE lasting less and more than 30 minutes, but we did not find 
any significant difference in their prevalence among incident a recurrent SE. 
Moreover, given the prospective assessment of the vast majority of clinical 
parameters and the large studied cohort, which is larger than the aforementioned 
population-based (183 in 10; 166 in 2; 150 in 11) and hospital-based analyses (107 in 6) 
taken together, we believe that this study adds important information regarding 
Tsetsou et al.   13  
current knowledge of the profile of SE patients at risk of recurrence. Early 
identification of such subjects may influence the management of their clinical follow-
up; furthermore, the awareness that a better prognosis in patients with SE relapse as 
compared to incident SE is not due to recurrence itself but rather to well-known SE 
outcome predictors related to the underlying SE severity and etiology, underscores the 
need of a clinical management tailored to the specific patient profile29. 
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The work described is consistent with the Journal’s guidelines for ethical publication.  
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Figures legends 
Figure 1A. Cumulative survival ratio without recurrence for the whole study cohort 
(Kaplan-Mayer). Figure 1B. Cumulative survival rate without recurrence; the light 
grey line represents patients with acute symptomatic etiology for the incident SE 
episode, the black line patients with non-acute symptomatic etiology. 
Figure 2: Mortality rates in incident / recurrent SE episode 
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Table 1: Demographic and clinical characteristics associated with recurrent as 
compared to incident SE episodes.  
  
  
Incident only 
SE 
n=509 
(episodes) 
Recurrent SE 
n=100 
(episodes) 
P Test 
Age (years) 
Mean= 61.03 Mean= 62.33 
P=0.524 t 
SD: 18.463 SD: 18.893 
Women 242 (48%) 68 (68%) P<0.001 Χ2 
STESS  
Median= 3 Median= 2 
 P<0.001 U 
(range=0-6) (range=0-5) 
Previous seizures  197 (39%) 100 (100%) P<0.001  Χ2 
Potentially fatal 
etiology 
271 (53%) 30 (30%) P<0.001 Χ2 
Acute symptomatic 
etiology 
303 (60%) 56 (56%) p=0.510 Χ2 
GCSE / NCSEC 233 (46%) 29 (29%) P=0.002 Χ2 
Time to 
treatment<1h 
185 (36%) 38 (38%) P=0.976 Χ2 
Refractory SE  
(>2 AED needed) 
173 (34%) 42 (42%) P=0.125 Χ2 
Intubation for 
treatment 
55 (11%) 6 (6%) P=0.143 Χ2 
Duration >30 
minutes 
470 (93%) 92 (92%) P=0.9 X2 
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SD= standard deviation, SE= status epilepticus, STESS= status epilepticus severity score, GCSE= 
generalized convulsive status epilepticus, NCSEC= non convulsive status epilepticus in coma, AED= 
antiepileptic drugs. 
 
 
Table 2: Variables (assessed during the incident SE episode) associated with SE 
recurrence (Cox regression analyses).  
 
 
Unadjusted Adjusted 
 
Hazard ratio 95% CI p Hazard ratio 95% CI p 
Gender (female) 1.49 0.91-2.43 0.09 1.59 0.97-2.65 0.060 
Age (older) 1 0.99-1.02 0.18   
 
  
Previous seizures 1.31 0.81-2.10 0.27   
 
  
Acute symptomatic etiology  0.52 0.32-0.84 <0.01 0.5 0.31-0.82 0.005 
Potential fatal etiology 0.84 0.51-1.36 0.47   
 
  
GCSE/NCSEC 0.79 0.49-1.28 0.34   
 
  
Duration <30 minutes 1.11 0.51-2.44 0.79   
 
  
STESS score (greater) 1.05 0.88-1.24 0.60   
 
  
Refractory SE (>2 AED needed) 1.16 0.68-1.97 0.59   
 
  
Intubation for treatment 1.69 0.84-3.40 0.15      
SE= status epilepticus, STESS= status epilepticus severity score, GCSE= generalized convulsive status 
epilepticus, NCSEC= non convulsive status epilepticus in coma, AED= antiepileptic drugs. 
 
 
 


